Loading
Trastuzumab deruxtecan shrank tumours in more than half of patients with previously treated HER2-mutant lung cancer, a driver with no approved therapy until this study, though lung inflammation was a serious side effect.
Phase 2 study of 91 patients with previously treated HER2-mutant metastatic non-small-cell lung cancer treated with trastuzumab deruxtecan 6.4 mg/kg.
Objective response was 55 percent with median duration of response 9.3 months, median progression-free survival 8.2 months and median overall survival 17.8 months; drug-related interstitial lung disease occurred in 26 percent with two deaths.
HER2 mutations, present in about 3 percent of lung adenocarcinomas, became actionable; trastuzumab deruxtecan received the first approval for a HER2-mutant lung cancer, at the lower 5.4 mg/kg dose validated in DESTINY-Lung02.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares DESTINY-Lung01, Trastuzumab deruxtecan.
Shares Trastuzumab deruxtecan, Trastuzumab, New England Journal of Medicine.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.
Shares HER2-mutant non-small-cell lung cancer, New England Journal of Medicine.
Shares HER2-mutant non-small-cell lung cancer, Trastuzumab deruxtecan.